17国按收入水平分组的二级预防药物使用:PURE前瞻性队列研究
基于PURE多国前瞻性队列,对基线及4次随访中确诊心血管病患者的二级预防药物使用进行重复横断面分析,中位随访12年。全球及多数收入组使用率低且改善有限,高收入国家使用率最高但下降,低/中低收入国家使用率低且波动。
要点
- 全球二级预防药物使用率低,中位随访12年仅轻微改善。
- 高收入国家使用率从88.8%降至77.3%,但仍远高于其他组。
- 低/中低收入国家使用率低且波动,最低仅13.4%。
核心结论
- 全球及多数国家收入组中,心血管病二级预防药物使用率低,随时间改善有限。
研究设计与样本
- PURE多国前瞻性队列研究的重复横断面分析,覆盖17个高、中、低收入国家。
- 分析纳入基线确诊心血管病者7409人,第2次随访8792人,第3次9236人,第4次11082人,末次11677人。
- 基线中位年龄58.0岁,女性占52.9%,中位随访12年,基线访视中位年份2007年,第5次访视2019年。
主要发现
- 使用至少1类二级预防药物的比例基线为41.3%(95%CI: 40.2%-42.4%),峰值43.1%(95%CI: 42.0%-44.1%),末次降至31.3%(95%CI: 30.4%-32.1%)。
- 高收入国家使用率从88.8%(95%CI: 86.6%-91.0%)降至77.3%(95%CI: 74.9%-79.6%)。
- 中高收入国家使用率从55.0%(95%CI: 52.8%-57.3%)升至61.1%(95%CI: 59.1%-63.1%)。
- 中低收入国家使用率基线29.5%(95%CI: 28.1%-30.9%),峰值31.7%(95%CI: 30.4%-33.1%),末次降至13.4%(95%CI: 12.5%-14.2%)。
- 低收入国家使用率基线20.8%(95%CI: 18.1%-23.5%),峰值47.3%(95%CI: 44.8%-49.9%),末次降至27.5%(95%CI: 25.2%-29.9%)。
临床怎么用
- 应关注全球二级预防药物使用不足,尤其低/中低收入国家。
- 高收入国家使用率下降提示需维持长期二级预防用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether global use of medications for secondary cardiovascular (CVD) prevention is improving over time. OBJECTIVES: This study across 17 high-, middle- and low-income countries described variations in secondary CVD prevention medication use over a median follow-up of 12 years. METHODS: In the multinational PURE (Prospective Urban Rural Epidemiology) cohort study, we conducted a repeated cross-sectional analysis to examine temporal variations in the use of secondary prevention medications in participants with CVD. In participants with coronary artery disease, we focused on antiplatelet agents, statins, renin-angiotensin system (RAS) inhibitors, and β-blockers. In participants with stroke, we focused on antiplatelet agents, statins, RAS inhibitors, and other blood pressure-lowering drugs. Medications were collected at baseline and on 4 subsequent follow-up visits. RESULTS: The analysis included 7,409 participants with a diagnosis of CVD at the baseline visit, 8,792 at the second visit, 9,236 at the third visit, 11,082 at the fourth visit, and 11,677 at the last visit. The median age at baseline was 58.0 years, and 52.9% of the participants were female. The median follow-up was 12 years, with the median year of the baseline visit in 2007 and the fifth visit in 2019. Over this period, use of 1 or more classes of medications for secondary CVD prevention was 41.3% (95% CI: 40.2%-42.4%) at baseline, peaked at 43.1% (95% CI: 42.0%-44.1%), and then decreased to 31.3% (95% CI: 30.4%-32.1%) by the last study visit. In high-income countries, this use decreased from 88.8% (95% CI: 86.6%-91.0%) to 77.3% (95% CI: 74.9%-79.6%). In upper-middle-income countries, this use increased from 55.0% (95% CI: 52.8%-57.3%) to 61.1% (95% CI: 59.1%-63.1%). In lower-middle-income countries, use of at least 1 class of medications was 29.5% (95% CI: 28.1%-30.9%) at baseline, peaked at 31.7% (95% CI: 30.4%-33.1%), and then decreased to 13.4% (95% CI: 12.5%-14.2%) by the last visit. In low-income countries, use of at least 1 class of medications was 20.8% (95% CI: 18.1%-23.5%) at baseline, peaked at 47.3% (95% CI: 44.8%-49.9%), and then decreased to 27.5% (95% CI: 25.2%-29.9%) by the last study visit. CONCLUSIONS: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.
引用
- Joseph P, Avezum Á, Ramasundarahettige C, et al. Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study. J Am Coll Cardiol. 2025. PMID: 39909677. doi:10.1016/j.jacc.2024.10.121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。